Group visits to help manage high cholesterol
Official title: Improving Care Through Group Medical Visits for Patients With Dyslipidemia
Run by Université de Sherbrooke · NCT07543718 · Data updated 2026-11-12
This project will try group medical visits for adults with dyslipidemia to see if they improve care, lifestyle habits, and access to primary care.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 40 Years and up |
| Sex | All |
| Enrollment | 288 (estimated) |
| Sponsor | Université de Sherbrooke Academic / other |
| Locations | 1 site (Dieppe, New Brunswick) |
| Status | Recruiting |
| Started | April 2026 |
| Main results expected | January 2030 |
| Study ends | December 2030 |
| Registry record updated | April 22, 2026 |
| Trial ID | NCT07543718 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults with dyslipidemia meeting Canadian Cardiovascular Society criteria — at minimum an intermediate Framingham cardiovascular risk (10–19.9%) with LDL‑C ≥ 3.5 mmol/L or non‑HDL‑C ≥ 4.2 mmol/L or ApoB ≥ 1.05 g/L — who can attend in-person group sessions and provide informed consent.
✕Probably not a fit
Patients unable to participate in group sessions, those with severe cognitive impairment or recent acute psychiatric decompensation, or those with a terminal illness and life expectancy under 12 months are unlikely to benefit.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
Group medical visits (GMVs) replace one-on-one primary care appointments with scheduled sessions for patients who share a condition, combining medical assessment, education, prescriptions, and peer discussion. This project will implement GMVs for 144 patients with dyslipidemia at a primary care unit in Dieppe, New Brunswick, and collect data on how the approach is delivered and received. Clinical indicators (including lipid levels), patient-reported outcomes, and health service use will be tracked alongside measures of feasibility and acceptability. The goal is to document whether GMVs can be integrated into routine primary care and whether they affect health behaviors, access, and clinical outcomes.
Why it matters
Potential benefit: If successful, GMVs could improve cholesterol control and lifestyle habits, increase access to primary care, and reduce pressure on healthcare services.
How similar studies have gone: GMVs have shown benefits for diabetes and other chronic conditions in prior studies, but they have not been specifically tested for dyslipidemia.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Diagnosis of dyslipidemia according to the guidelines of the Canadian Cardiovascular Society, i.e., at a minimum: an intermediate cardiovascular risk according to the Framingham Risk Score (10-19.9%) WITH LDL-C ≥ 3.5 mmol/L or non-HDL-C ≥ 4.2 mmol/L or ApoB ≥ 1.05 g/L Exclusion Criteria: * Patients unable to participate in GMV sessions or to provide informed consent * Patients with a mental health condition likely to limit their ability to benefit from GMV sessions and discussions (Examples: severe dementia or an acute psychiatric decompensation occurring within the past six months) * A diagnosis of terminal illness or a life expectancy of less than 12 months
Where it's running
-
Unité de médecine familiale du Grand-Moncton
Dieppe, New Brunswick, Canada Recruiting
Study contacts
- Study coordinator: Mathieu Belanger, PhD
- Email: mathieu.f.belanger@usherbrooke.ca
- Phone: 5068632221
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Asprosin and miRNA Profiles in Young Women with Metabolic Syndrome
This study tests whether certain blood biomarkers, including asprosin and six microRNAs, differ between young women with metabolic syndrome and healthy peers.
-
Home-based cardiovascular health screening for people turning 50, 55, 60, 65, 70 or 75 in Uppsala
This trial tests whether giving people a home blood pressure monitor, a dried blood spot kit, and a questionnaire can find more cardiovascular risk factors than usual care.
-
Fixed-dose pitavastatin/ezetimibe for adults with dyslipidemia and metabolic syndrome
This will try a fixed-dose pitavastatin/ezetimibe pill in adults with dyslipidemia and metabolic syndrome to see if it lowers LDL cholesterol and is safe over 48 weeks.
-
CTX310 for refractory high triglycerides or LDL cholesterol
This trial will test whether a single IV dose of CTX310 is safe and tolerated in adults whose high triglycerides or LDL cholesterol have not responded to available treatments.
-
Taining Golden Lake comprehensive chronic disease management program
This project will build a large cohort of adults in Taining County to collect health data and try to create a county-level chronic disease management model for people with hypertension, diabetes, dyslipidemia, and other long-term conditions.
-
Fixed-dose pitavastatin plus ezetimibe for lowering cholesterol
This will try a single pill combining pitavastatin and ezetimibe to lower cholesterol in adults who have been stable on atorvastatin or rosuvastatin.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.